Assessing the Impact of a Matching-Adjusted Indirect Comparison in a Bayesian Network Meta-Analysis

Autor/inn/en	Leahy, Joy; Walsh, Cathal
Titel	Assessing the Impact of a Matching-Adjusted Indirect Comparison in a Bayesian Network Meta-Analysis
Quelle	In: Research Synthesis Methods, 10 (2019) 4, S.546-568 (23 Seiten)Infoseite zur Zeitschrift PDF als Volltext Verfügbarkeit
Zusatzinformation	ORCID (Leahy, Joy) ORCID (Walsh, Cathal)
Sprache	englisch
Dokumenttyp	gedruckt; online; Zeitschriftenaufsatz
ISSN	1759-2879
DOI	10.1002/jrsm.1372
Schlagwörter	Comparative Analysis; Meta Analysis; Bayesian Statistics; Network Analysis; Medical Research; Outcomes of Treatment; Drug Therapy; Oncology; Clinical Diagnosis; Patients + Suchen Sie Ihr Suchwort? Meta-analysis; Metaanalyse; Netzplantechnik; Onkologie; Patient
Abstract	If IPD is available for some or all trials in a network meta-analysis (NMA), then incorporating this IPD into an NMA is routinely considered to be preferable. However, the situation often arises where a researcher has IPD for trials concerning a particular treatment (eg, from a sponsor) but none for other trials. Therefore, one can reweight the IPD so that the covariate characteristics in the IPD trials match that of the aggregate data (AgD) trials, using a matching-adjusted indirect comparison (MAIC). We assess the impact of using the reweighted aggregated data, obtained by the MAIC, in a Bayesian NMA for a connected treatment network. We apply this method to a network of multiple myeloma treatments in newly diagnosed patients (ndMM), where the outcome is progression free survival. We investigate the reliability of the methods and results through a simulation study. The ndMM network consists of three IPD studies comparing lenalidomide to placebo (Len-Placebo), one AgD study comparing Len-Placebo, and one AgD study comparing thalidomide to placebo (Thal-Placebo). We therefore investigate two options of weighting the covariates: (a) All three studies are weighted separately to match the AgD Thal-Placebo trial. (b) Patients are weighted across all three IPD studies to match the AgD Thal-Placebo trial, but the NMA considers each trial separately. We observe limited benefit to MAIC in the full network population. While MAIC can be beneficial as a sensitivity analysis to confirm results across patient populations, we advise that MAIC is used and interpreted with caution. (As Provided).
Anmerkungen	Wiley-Blackwell. 350 Main Street, Malden, MA 02148. Tel: 800-835-6770; Tel: 781-388-8598; Fax: 781-388-8232; e-mail: cs-journals@wiley.com; Web site: http://www.wiley.com/WileyCDA
Erfasst von	ERIC (Education Resources Information Center), Washington, DC
Update	2024/1/01